145 related articles for article (PubMed ID: 37291665)
1. Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors.
Mönch S; Heimer MM; Winkelmann M; Guertler A; Schlaak M; Tufman A; Ben Khaled N; de Toni E; Westphalen CB; von Bergwelt-Baildon M; Dinkel J; Kazmierczak PM; Ingrisch M; Mansour N; Unterrainer M; Heinzerling L; Ricke J; Kunz WG
Cancer Imaging; 2023 Jun; 23(1):58. PubMed ID: 37291665
[TBL] [Abstract][Full Text] [Related]
2. Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.
Colle R; Radzik A; Cohen R; Pellat A; Lopez-Tabada D; Cachanado M; Duval A; Svrcek M; Menu Y; André T
Eur J Cancer; 2021 Feb; 144():9-16. PubMed ID: 33316636
[TBL] [Abstract][Full Text] [Related]
3. Pseudoprogression and Mixed Responses in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab: A Retrospective Analysis.
Haaker L; Baldewijns M; De Wever L; Albersen M; Debruyne PR; Wynendaele W; De Meerleer G; Beuselinck B
Clin Genitourin Cancer; 2023 Aug; 21(4):442-451. PubMed ID: 36997468
[TBL] [Abstract][Full Text] [Related]
4. Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types.
Martin-Romano P; Castanon E; Ammari S; Champiat S; Hollebecque A; Postel-Vinay S; Baldini C; Varga A; Michot JM; Vuagnat P; Marabelle A; Soria JC; Ferté C; Massard C
Cancer Med; 2020 Apr; 9(8):2643-2652. PubMed ID: 32074405
[TBL] [Abstract][Full Text] [Related]
5. Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs.
Guiard E; Baldini C; Pobel C; Assi T; Bernard-Tessier A; Martin-Romano P; Hollebecque A; Verlingue L; Geraud A; Michot JM; Armand JP; Soria JC; Massard C; Ammari S
Eur J Cancer; 2022 May; 167():42-53. PubMed ID: 35378410
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy.
Zheng B; Shin JH; Li H; Chen Y; Guo Y; Wang M
Korean J Radiol; 2021 Mar; 22(3):366-375. PubMed ID: 33289356
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitor-Induced Cerebral Pseudoprogression: Patterns and Categorization.
Urban H; Steidl E; Hattingen E; Filipski K; Meissner M; Sebastian M; Koch A; Strzelczyk A; Forster MT; Baumgarten P; Ronellenfitsch MW; Steinbach JP; Voss M
Front Immunol; 2021; 12():798811. PubMed ID: 35046955
[TBL] [Abstract][Full Text] [Related]
8. Patterns of progression in patients treated for immuno-oncology antibodies combination.
Bernard-Tessier A; Baldini C; Castanon E; Martin P; Champiat S; Hollebecque A; Postel-Vinay S; Varga A; Bahleda R; Gazzah A; Michot JM; Ribrag V; Armand JP; Marabelle A; Soria JC; Massard C; Ammari S
Cancer Immunol Immunother; 2021 Jan; 70(1):221-232. PubMed ID: 32700090
[TBL] [Abstract][Full Text] [Related]
9. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
10. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria.
Tazdait M; Mezquita L; Lahmar J; Ferrara R; Bidault F; Ammari S; Balleyguier C; Planchard D; Gazzah A; Soria JC; Marabelle A; Besse B; Caramella C
Eur J Cancer; 2018 Jan; 88():38-47. PubMed ID: 29182990
[TBL] [Abstract][Full Text] [Related]
11. [Monitoring of immunotherapy : Possibilities and limitations].
Schneider H; Illert AL; Bamberg F; Eisenblätter M
Radiologe; 2020 Aug; 60(8):711-720. PubMed ID: 32710153
[TBL] [Abstract][Full Text] [Related]
12. Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival.
Xie P; Zheng H; Chen H; Wei K; Pan X; Xu Q; Wang Y; Tang C; Gevaert O; Meng X
BMC Cancer; 2021 Nov; 21(1):1246. PubMed ID: 34798858
[TBL] [Abstract][Full Text] [Related]
13. Prospective Assessment of Fluorine-18-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography (FDG-PET/CT) for Early Identification of Checkpoint-Inhibitor-Induced Pseudoprogression.
Homburg S; Christensen CB; Pedersen M; Sørensen SG; Donia M; Svane IM; Hendel HW; Ellebaek E
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473325
[TBL] [Abstract][Full Text] [Related]
14. Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis.
Park HJ; Kim KW; Pyo J; Suh CH; Yoon S; Hatabu H; Nishino M
Radiology; 2020 Oct; 297(1):87-96. PubMed ID: 32749204
[TBL] [Abstract][Full Text] [Related]
15. Incidence of pseudoprogression in low-grade gliomas treated with radiotherapy.
van West SE; de Bruin HG; van de Langerijt B; Swaak-Kragten AT; van den Bent MJ; Taal W
Neuro Oncol; 2017 May; 19(5):719-725. PubMed ID: 28453748
[TBL] [Abstract][Full Text] [Related]
16. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer.
Dolladille C; Ederhy S; Sassier M; Cautela J; Thuny F; Cohen AA; Fedrizzi S; Chrétien B; Da-Silva A; Plane AF; Legallois D; Milliez PU; Lelong-Boulouard V; Alexandre J
JAMA Oncol; 2020 Jun; 6(6):865-871. PubMed ID: 32297899
[TBL] [Abstract][Full Text] [Related]
18. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
[TBL] [Abstract][Full Text] [Related]
19. Atypical patterns of response and progression in the era of immunotherapy combinations.
Ferrara R; Matos I
Future Oncol; 2020 Aug; 16(23):1707-1713. PubMed ID: 32687405
[TBL] [Abstract][Full Text] [Related]
20. Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard?
Melguizo-Gavilanes I; Bruner JM; Guha-Thakurta N; Hess KR; Puduvalli VK
J Neurooncol; 2015 May; 123(1):141-50. PubMed ID: 25894594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
